German A Gil
Overview
Explore the profile of German A Gil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peralta M, Mendieta S, Scolari I, Gerbaldo M, Oliva M, Gil G, et al.
Heliyon
. 2023 Nov;
9(10):e21030.
PMID: 37916071
Current cancer chemotherapy is associated with many side effects and, in some cases, drug resistance, which makes the search for new active molecules and drug delivery strategies imperative. Carbamazepine is...
2.
Nigra A, Teodoro A, Gil G
Oxid Med Cell Longev
. 2021 Sep;
2021:4420479.
PMID: 34567408
Coffee consumption has been investigated as a protective factor against cancer. Coffee is a complex beverage that contains more than 1000 described phytochemicals, which are responsible for its pleasant taste,...
3.
Nigra A, de Almeida Bauer Guimaraes D, Prucca C, Freitas-Silva O, Teodoro A, Gil G
Oxid Med Cell Longev
. 2021 Jun;
2021:5572630.
PMID: 34113419
Coffee consumption is believed to have chemopreventive and chemotherapeutic effects and to contribute to preventing the development and progression of cancer. However, there is still controversy around these claims. As...
4.
Carbajosa S, Pansa M, Paviolo N, Castellaro A, Andino D, Nigra A, et al.
Clin Cancer Res
. 2019 Mar;
25(13):4049-4062.
PMID: 30890549
Purpose: BRCA1 and BRCA2 deficiencies are widespread drivers of human cancers that await the development of targeted therapies. We aimed to identify novel synthetic lethal relationships with therapeutic potential using...
5.
Castellaro A, Rodriguez-Baili M, Di Tada C, Gil G
Cancers (Basel)
. 2019 Feb;
11(2).
PMID: 30736340
Antiestrogenic adjuvant treatments are first-line therapies in patients with breast cancer positive for estrogen receptor (ER+). Improvement of their treatment strategies is needed because most patients eventually acquire endocrine resistance...
6.
Castellaro A, Tonda A, Cejas H, Ferreyra H, Caputto B, Pucci O, et al.
BMC Cancer
. 2015 Oct;
15:761.
PMID: 26493452
Background: Microcalcifications can be the early and only presenting sign of breast cancer. One shared characteristic of breast cancer is the appearance of mammographic mammary microcalcifications that can routinely be...
7.
Caputto B, Cardozo Gizzi A, Gil G
Biochim Biophys Acta
. 2014 Jun;
1841(9):1241-6.
PMID: 24886961
The mechanisms that co-ordinately activate lipid synthesis when high rates of membrane biogenesis are needed to support cell growth are largely unknown. c-Fos, a well known AP-1 transcription factor, has...
8.
Ferrero G, Renner M, Gil G, Rodriguez-Berdini L, Caputto B
Biochem J
. 2014 May;
461(3):521-30.
PMID: 24819416
c-Fos is a well-recognized member of the AP-1 (activator protein-1) family of transcription factors. In addition to this canonical activity, we previously showed that cytoplasmic c-Fos activates phospholipid synthesis through...
9.
Gil G, Silvestre D, Tomasini N, Bussolino D, Caputto B
Neurochem Res
. 2012 Apr;
37(6):1364-71.
PMID: 22476983
Some 20 years ago c-Fos was identified as a member of the AP-1 family of inducible transcription factors (Angel and Karin in Biochim Biophys Acta 1072:129-157, 1991). More recently, an...
10.
Silvestre D, Gil G, Tomasini N, Bussolino D, Caputto B
PLoS One
. 2010 Mar;
5(3):e9544.
PMID: 20209053
Background: We have previously shown that the transcription factor c-Fos is also capable of associating to endoplasmic reticulum membranes (ER) and activating phospholipid synthesis. Herein we examined phospholipid synthesis status...